MutL Protein Homolog 1

Eukaryotic homolog of the bacterial MutL DNA MISMATCH REPAIR protein. It heterodimerizes with MISMATCH REPAIR ENDONUCLEASE PMS2 to form MutL alpha, which is recruited to DNA mismatch sites by the MUTS DNA MISMATCH-BINDING PROTEIN. Mutations in the human MLH1 gene are associated with COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS.

Also Known As:

Networked: 236 relevant articles (0 outcomes, 31 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Broaddus, Russell R: 4 articles (01/2018 - 11/2005)
2.	Gallinger, Steven: 4 articles (01/2017 - 01/2012)
3.	Peltomäki, Päivi: 3 articles (07/2020 - 07/2005)
4.	Losi, Lorena: 3 articles (11/2019 - 01/2004)
5.	Furukawa, Yoichi: 3 articles (08/2019 - 12/2012)
6.	Goodfellow, Paul J: 3 articles (01/2019 - 10/2006)
7.	Llor, Xavier: 3 articles (01/2018 - 07/2010)
8.	Murawaki, Yoshikazu: 3 articles (09/2017 - 09/2003)
9.	Yashima, Kazuo: 3 articles (09/2017 - 09/2003)
10.	Savio, Andrea J: 3 articles (01/2017 - 01/2012)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "In this study, we assessed the microbial composition and diversity of SCRC tumors with varying MutL protein homolog 1 (MLH1) status, and the effects of functional genes related to bacterial markers and clinical diagnostic prediction. " 05/01/2017 - "Many studies have demonstrated that human mutL homolog 1(hMLH1) promoter methylation is correlated with occurrence and progression of multiple types of tumors. " 03/01/2002 - "The aim of the present study was to determine whether immunohistochemical examination of MSH2 or MLH1 protein expression in MTS-associated skin tumors can be used as a diagnostic screening tool to identify patients with germline mutations in MSH2 or MLH1. " 04/25/2023 - "Immunohistochemical analysis revealed the loss of MutL homolog 1 (MLH1) and postmeiotic segregation increased 2 (PMS2) expression in the cancer cells of biopsied specimens, suggesting deficient mismatch repair (dMMR). " 09/20/2022 - "Eighty percent of neoplasms with MLH1 protein loss had a concurrent MLH1 promoter methylation analysis. "
2.	Colorectal Neoplasms (Colorectal Cancer) 10/01/2018 - "There has been increasing interest in the study of the association between human mutL homolog 1 (hMLH1) gene polymorphisms and risk of colorectal cancer (CRC). " 01/01/2018 - "Several studies suggested that promoter methylation of human mutL homolog 1 (hMLH1) was associated with the risk of colorectal cancer (CRC). " 01/01/2015 - "The aim of the present study was to analyze the relationship between aberrant human mutL homolog 1 (hMLH1) expression and clinicopathological parameters of patients with sporadic colorectal cancer, and to explore the prognostic effect of aberrant hMLH1 expression in these patients. " 01/01/2019 - "Expression of the mismatch repair gene MutL homolog 1 (MLH1) is silenced in a clinically important subgroup of sporadic colorectal cancers. " 11/08/2018 - "Immunohistochemistry for BRAF V600E was performed in colorectal cancers with loss of MLH1 protein expression. "
3.	Microsatellite Instability 04/01/2019 - "The aim of the present study was to stratify CRC patients using molecular diagnostics and next generation sequencing, according to the chosen criteria [positive for microsatellite instability (MSI) and negative for a BRAF mutation and MutL homolog 1 (MLH1) methylation], and subsequently to detect pathological germline mutations in MMR genes in Slovak patients. " 12/15/2021 - "In CRC, the silencing of mismatch repair genes, including the mutL homolog 1 (hMLH1) has been linked to microsatellite instability (MSI), the lengthening or shortening of microsatellite repeats. " 12/01/2020 - "The histology, mutation profile, MutL homolog 1 promoter methylation, copy‑number variation, homologous recombination repair and microsatellite instability in each of these cell lines was assessed. " 03/01/2019 - "The rate of patients with lesions containing both mutL homolog 1 (MLH1) methylation and microsatellite stable status was 66.7% in those with synchronous CRC, with at least one lesion with high microsatellite instability. " 11/01/2013 - "All MLH1 protein-negative cases were subjected to microsatellite instability analysis and MLH1 promoter methylation assay. "
4.	Carcinoma (Carcinomatosis) 05/01/2017 - "In vitro study of human mutL homolog 1 hypermethylation in inducing drug resistance of esophageal carcinoma." 07/01/2009 - "Absent MLH1 protein expression with no gene mutations were identified in carcinoma in situ and nodular-trabecular urothelial carcinoma with high microsatellite abnormalities. " 07/14/2009 - "We evaluated BRCA1, BRCA2, and MLH1 protein expression in 115 sporadic primary ovarian carcinomas, of which 31 had paired recurrent neoplasms collected after chemotherapy. " 06/01/2001 - "A high incidence of defective MSH2 and MLH1 protein in endometrial carcinoma with multiple primary carcinomas, however, suggests that abnormalities in the function of MSH2 and MLH1 may play an important role in tumorigenesis for patients with endometrial carcinoma with multiple primary carcinomas and their families." 02/01/2006 - "Mutation of human mutL homolog 1 (MLH-1) and human mutS homolog 2 (MSH-2) has been linked with the pathogenesis of colorectal carcinoma in hereditary nonpolyposis colorectal cancer syndrome and other carcinomas. "
5.	Endometrial Neoplasms (Endometrial Cancer) 01/01/2010 - "The PTEN and MLH1 protein immunoexpression was also examined separately in both clinicopathological groups of endometrial carcinoma. " 01/01/2019 - "The aim of this study was to evaluate outcomes of MMR immunohistochemistry (IHC), mutL homolog 1 (MLH1) methylation, and microsatellite instability (MSI) analysis among patients with endometrial cancer. " 03/01/2015 - "The aim of this study was to determine the genetic risk for developing endometrial cancer by immunohistochemical staining of premalignant lesions for mutL homolog 1, mutS homolog 2, mutS homolog 6, and postmeiotic segregation increased 2. Twenty cases (n=20) were selected from among patients with available sample blocks for analysis. " 11/01/2005 - "There is some evidence that endometrial complex hyperplasia demonstrating loss of MLH1 protein by immunohistochemistry is strongly related to subsequent or concurrent endometrial cancer, especially tumors of higher grade and stage. " 06/01/2001 - "A high incidence of defective MSH2 and MLH1 protein in endometrial carcinoma with multiple primary carcinomas, however, suggests that abnormalities in the function of MSH2 and MLH1 may play an important role in tumorigenesis for patients with endometrial carcinoma with multiple primary carcinomas and their families."

Related Drugs and Biologics

1.	MutS Proteins
2.	Proteins (Proteins, Gene)
3.	Methyltransferases
4.	MutL Protein Homolog 1
5.	DNA (Deoxyribonucleic Acid)
6.	Phosphoric Monoester Hydrolases (Phosphatases)
7.	Tensins
8.	Estrogen Receptor alpha
9.	O(6)-Methylguanine-DNA Methyltransferase
10.	Histidine (L-Histidine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Adjuvant Chemotherapy
4.	Brachytherapy
5.	Semiconductors